



UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. MBHB02-763-B; 400/129)

IN THE APP	LICATION OF:)		
McSwiggen, et al.)		
Serial No.	10/667,271)	Examiner:	TBA
Filed:	September 16, 2003)	Group Art Unit:	1632
Title	RNA Interference Mediated Inhibition Of Hepatitis C VIRUS (HCV) Gene Expression Using Short Interfering Nucleic Acid (siNA))	Confirmation No.:	8658

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop OIPE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examination's Filing Receipts Corrections

- 1. Attached is a copy of the filing receipt received from the PTO in the above-referenced application for which issuance of a new corrected filing receipt is respectfully requested.
- 2. There is an error with respect to the following data, which is incorrectly entered.

Error in

Domestic Priority data as claimed by applicant: This application is a CIP of 10/444,853 05/23/2003 and is a CIP of PCT/US03/05043 02/20/2003

and is a CIP of PCT/US02/09187 03/26/2002

and said PCT/US03/05043 02/20/2003 claims benefit of 60/401,104 08/05/2002 and claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003

Correct Data

Domestic Priority data as claimed by applicant:
This application is a CIP of 10/444,853 05/23/2003
and is a CIP of PCT/US03/05043 02/20/2003
and said PCT/US03/05043 02/20/2003
is a CIP of PCT/US02/09187 03/26/2002
and said PCT/US03/05043 02/20/2003
claims benefit of 60/401,104 08/05/2002
and claims benefit of 60/358,580 02/20/2002
and claims benefit of 60/363,124 03/11/2002
and claims benefit of 60/386,782 06/06/2002
and claims benefit of 60/406,784 08/29/2002
and claims benefit of 60/408,378 09/05/2002
and claims benefit of 60/409,293 09/09/2002
and claims benefit of 60/440,129 01/15/2003

The correction is not due to any error by applicant and no fee is due. 3.

Respectfully submitted, McDonnell, Boehnen, Hulbert & Berghoff

Date: February <u>18</u>, 2004

Registration No. 47,132



020306

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United Office Patent and Trademark Office
Address AMMISSIONER FOR PATENTS
Alexandra, Vigorous 22313-1450
www.usplo.gov

FILING OR 371 ATTY.DOCKET NO TOT CLMS IND CLMS DRAWINGS ART UNIT FIL FEE REC'D (c) DATE 2 MBHB02-763-B (400/129) 35 510 10/667,271 09/16/2003 1632

CONFIRMATION NO. 8658

FILING RECEIPT

FEB 2 3 200

OC000000011607252

MCDONNELL BOEHNEN HULBERT & BERGHOFF

SUITE 3200 CHICAGO, IL 60606

300 SOUTH WACKER DRIVE

Date Mailed: 01/02/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James McSwiggen, Boulder, CO; Leonid Beigelman, Longmont, CO; Dennis Macejak, Arvada, CO;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/444,853 05/23/2003 and is a CIP of PCT/US03/05043 02/20/2003 and is a CIP of PCT/US02/09187 03/26/2002 and said PCT/US03/05043 02/20/2003 claims benefit of 60/401,104 08/05/2002 and claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003

This application is a CIP of 10/444, 853 05/23/2003 and is a cip of pct/us03/05043 02/20/2003 and said PCI/US03/05043 02/20/2003 is a cip of pct/us/02/09/87 03/26/2002 and said PCT/US03/05043 02/20/2003 claims benefit of 60/401,104 08/05/2002 and claims benefit of 60/358,580 oz/20/2002 and claims benefit of 60/363,124 03/11/2002 claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/406,784 08/29/2012 claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409, 293 09/09/2002 and claims henefit of 60/440,129 01/15/2003

Foreign Applications

UNITED STATES OF AMERICA PCT/US03/05043 02/20/2003 UNITED STATES OF AMERICA PCT/US02/09187 03/26/2002

If Required, Foreign Filing License Granted: 01/02/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PATENT



UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. MBHB02-763-B; 400/129)

IN THE APPL	ICATION OF:)	
McSw	iggen et al.)	
Serial No.	10/667,271) Examiner:	TBA
Filed:	September 16, 2003) Group Art Unit:	1632
Title	RNA Interference Mediated Inhibition Of Hepatitis C VIRUS (HCV) Gene Expression Using Short Interfering Nucleic Acid (siNA)	Confirmation No.:)))	8658

Mail Stop OIPE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examination's

Filing Receipts Corrections

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - a. Request for Corrected Filing Receipt
 - b. Copy of Filing Receipt
 - c. Return Receipt Postcard.
- 2. With respect to additional fees,
 - It is believed no fee is due at this time.
- 3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No.13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop OIPE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February <u>18</u>, 2004.

Date: February 18, 2004

McDONNELL BOEHNEN, HULBERT & BERGHOFF 300 SOUTH WACKER DRIVE, 32[™] FLOOR CHICAGO, ILLINOIS 60606 TELEPHONE (312) 913-0001 FACSIMILE (312) 913-0002